Share on LinkedInShare on LinkedIn

ARTICLE · 03 AUGUST 2023

Update: Post-Trial Briefing In Regeneron v. Mylan Aflibercept BPCIA Case Now Complete

The parties submitted their responsive briefs on July 24, 2023, along with proposed findings of fact and conclusions of law.

United StatesIntellectual Property

We previously reported on the opening post-trial briefs in Regeneron's BPCIA case against Mylan and Biocon (who was added as a defendant after the original defendant, Mylan, transferred its rights to the aflibercept biosimilar to Biocon). Now, post-trial briefing is complete.

The parties submitted their responsive briefs on July 24, 2023, along with proposed findings of fact and conclusions of law. Both sides' papers were filed under seal. The parties submitted their reply briefs on July 28, 2023. Defendants' reply brief is publicly available.

In their 10-page reply brief, Defendants continued to press their invalidity arguments. Specifically, Defendants argued that the asserted claims of the dosing patents (the '601 and '572 patents) are anticipated, obvious, lacking written description, not enabled, and/or indefinite. Likewise for the formulation patent (the '865 patent), Defendants argued that the asserted claims are anticipated, obvious, lacking

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from